文献速递临床试验与 GCP新药、器械与细胞基因治疗研发组学、生物样本库与精准医学

补肾降压颗粒对低中危高血压患者血压及药物基因组学评价的影响:随机双盲对照试验研究方案

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial.
PubMed 文献 · Trials · 2022-01-15

本研究为单中心随机双盲安慰剂对照试验,计划纳入260例低中危高血压患者,按1:1随机分为补肾降压颗粒联合氨氯地平组与安慰剂联合氨氯地平组,干预期8周。主要结局为24小时平均收缩压和舒张压变化,次要结局包括心率变异性、药物基因组学评价、中医证候改善及血清促炎/抗炎细胞因子,并评价用药安全性。

要点

  • 补肾降压颗粒联合氨氯地平与安慰剂联合氨氯地平在低中危高血压患者中进行随机双盲对照比较。
  • 主要结局为24小时平均收缩压和舒张压变化,干预期8周。
  • 次要结局包括心率变异性、药物基因组学评价、中医证候改善及血清促炎/抗炎细胞因子。

核心结论

  • 作者假设低中危高血压患者将从补肾降压颗粒中获益;若研究成功,将为临床医生提供循证推荐。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照试验,计划纳入260例受试者,按1:1比例随机分为试验组(补肾降压颗粒联合氨氯地平)和对照组(安慰剂联合氨氯地平),试验周期8周。

主要发现

  • 原文为研究方案,未报告试验结果。

关键数值与推荐

  • 主要结局为24小时平均收缩压和舒张压的变化。
  • 次要结局包括两组间心率变异性、药物基因组学评价、中医证候改善及血清促炎/抗炎细胞因子的比较,并评价用药安全性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hypertension is one of the most important risk factors for cardiovascular disease, and its control rates remain low worldwide. The most effective strategy is that patients with hypertension should be diagnosed and treated early. Preliminary studies showed that the Bushen Jiangya granule (BSJY) could suppress ventricular hypertrophy and inflammatory responses, lower blood pressure, and protect the target organs of hypertension. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of BSJY in patients with low-to-medium risk hypertension. METHODS AND ANALYSIS: This trial is a one-center, randomized, double-blind, placebo-controlled study. A total of 260 participants will be randomized in a 1:1 ratio to an experimental group (BSJY plus amlodipine) and a control group (placebo plus amlodipine). The trial cycle will last 8 weeks. The primary outcome is the change in 24-h average systolic and diastolic blood pressure. The secondary outcomes include heart rate variability, pharmacogenomic evaluation, improvement in TCM syndrome, and serum pro-inflammatory/anti-inflammatory cytokines between the two groups. The safety of medication will also be evaluated. All the data will be recorded in electronic case report forms and analyzed by SPSS V.22.0. ETHICS AND DISSEMINATION: This study has been approved by the Research Ethics Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences in Beijing, China (No. 2019-186-KY-01). The participants are volunteers, understand the process of this trial, and sign an informed consent. The results of this study will be disseminated to the public through peer-reviewed journals and academic conferences. DISCUSSION: We hypothesize that patients with low-to-medium-risk hypertension will benefit from BSJY. If successful, this study will provide evidence-based recommendations for clinicians. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiMCTR1900002876. Registered in November 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yang X, Liu L, Xiong X, et al. Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial. Trials. 2022. PMID: 35033168. doi:10.1186/s13063-022-05999-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。